Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

RHOA E40Q Loss of Wild-Type Allele Drives Squamous Cancer in JCI Study

JCI study shows RHOA E40Q drives squamous tumorigenesis only when wild-type RhoA is absent, linking replication stress to genome instability.

By Dr. Revathy Mohan V.R., MBBS · Oct 18, 2026 · 5 min read

Oncology·ScienceDaily

Dairy Awareness Gap Could Shape Prostate Cancer Prevention

A U.S. survey found most men did not know dairy was linked to prostate cancer risk, while many…

Oct 18, 2026

Oncology·ScienceDaily

Cord Blood T Cells Control Solid Tumors in UCLA Mouse Study

UCLA researchers engineered cord blood T cells to attack solid tumors in mice, pointing to an off-the-shelf cell…

Oct 18, 2026

Oncology·Med Econ

Pancreatic Cancer AI Detects Disease on CT Up to 3 Years Early

Mayo Clinic’s REDMOD model identified 73% of prediagnostic pancreatic cancers on routine CT, often years before clinical diagnosis.

Oct 18, 2026

Oncology·WHO

Africa’s role in precision oncology grows after Windhoek genomics conference

Windhoek conference synthesis outlines Africa’s genomic diversity, registry gaps, and the infrastructure needed to advance precision oncology.

Oct 18, 2026

Oncology·Nature

Mantle Cell Lymphoma Survival Improves Across Therapeutic Eras in SEER Study

SEER-17 data show steadily falling mantle cell lymphoma mortality from 2000 to 2023, with survival gains extending into…

Oct 18, 2026

Oncology·Nature

ENKL Transplant Meta-Analysis Examines AutoSCT vs AlloSCT

A systematic review in extranodal NK/T-cell lymphoma compares autologous and allogeneic stem cell transplantation and defines the key…

Oct 18, 2026

Oncology·JCI

Wilms Tumor snRNA-seq Maps Blastema Heterogeneity and Lineage Plasticity

Single-nucleus RNA sequencing of favorable-histology Wilms tumor reveals blastemal heterogeneity, stromal markers in tumor cells, and developmental lineage…

Oct 18, 2026

Oncology·Med Econ

GLP-1 Drugs Linked to Better Breast Cancer Survival in New Update

A morning medical update flagged an association between GLP-1 drugs and improved breast cancer survival, while other headlines…

Oct 18, 2026

Oncology·JCI

EGFR activation may blunt immunotherapy via SHP2 and IFN-γ suppression

JCI study links EGFR activation to impaired immunotherapy response through SHP2-mediated suppression of tumor-intrinsic IFN-γ signaling.

Oct 18, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.